Innoviva Gestion

Gestion contrôle des critères 4/4

Le PDG Innoviva est Pavel Raifeld, nommé en May2020, a un mandat de 4.5 ans. La rémunération annuelle totale est $ 868.65K, composée du salaire de 55.8% et des bonus 44.2%, y compris les actions et options de la société. détient directement 0.019% des actions de la société, d'une valeur de $ 223.46K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.9 ans et 6.8 ans.

Informations clés

Pavel Raifeld

Directeur général

US$868.6k

Rémunération totale

Pourcentage du salaire du PDG	55.8%
Durée du mandat du directeur général	4.5yrs
Propriété du PDG	0.02%
Durée moyenne d'occupation des postes de direction	2.9yrs
Durée moyenne du mandat des membres du conseil d'administration	6.8yrs

Mises à jour récentes de la gestion

Recent updates

Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price

Jul 26

Innoviva: Potentially Overvalued

Jun 21

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

May 21

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Mar 04

Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

Jan 15

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Dec 25

Will Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Prove Temporary Given Strong Fundamentals?

Dec 04

Innoviva: Only For Short-Term Traders

Nov 04

Innoviva reports Q3 results

Oct 28

Analyse de la rémunération des PDG

Comment la rémunération de Pavel Raifeld a-t-elle évolué par rapport aux bénéfices de Innoviva?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	US$65m
Jun 30 2024	n/a	n/a	US$145m
Mar 31 2024	n/a	n/a	US$181m
Dec 31 2023	US$869k	US$485k	US$180m
Sep 30 2023	n/a	n/a	US$50m
Jun 30 2023	n/a	n/a	US$233m
Mar 31 2023	n/a	n/a	US$233m
Dec 31 2022	US$2m	US$440k	US$214m
Sep 30 2022	n/a	n/a	US$293m
Jun 30 2022	n/a	n/a	US$99m
Mar 31 2022	n/a	n/a	US$188m
Dec 31 2021	US$1m	US$391k	US$266m
Sep 30 2021	n/a	n/a	US$309m
Jun 30 2021	n/a	n/a	US$265m
Mar 31 2021	n/a	n/a	US$253m
Dec 31 2020	US$2m	US$222k	US$224m

Rémunération vs marché: La rémunération totale de Pavel ($USD 868.65K ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 3.17M ).

Rémunération et revenus: La rémunération de Pavel a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Pavel Raifeld (40 yo)

4.5yrs

Titularisation

US$868,648

Compensation

Mr. Pavel Raifeld, CFA, is Director of La Jolla Pharmaceutical Company since August 22, 2022. He serves as Chief Executive Officer of Innoviva, Inc. since May 2020. He is a seasoned healthcare executive wi...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Pavel Raifeld	Chief Executive Officer	4.5yrs	US$868.65k	0.019% $ 223.5k
Stephen Basso	Chief Financial Officer	1.3yrs	US$1.18m	pas de données
Marianne Zhen	Chief Accounting Officer & Secretary	6.3yrs	US$924.21k	0.073% $ 873.6k
Patricia Drake	Chief Commercial Officer-Innoviva Specialty Therapeutics	less than a year	pas de données	pas de données

2.9yrs

Durée moyenne de l'emploi

56.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de INVA est considérée comme expérimentée (ancienneté moyenne 2.9 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Jules Haimovitz	Independent Director	6.8yrs	US$446.02k	0.19% $ 2.2m
Sapna Srivastava	Independent Director	1.8yrs	US$547.11k	0.041% $ 487.6k
Derek Small	Independent Director	less than a year	pas de données	pas de données
Odysseas Kostas	Independent Director	6.9yrs	US$331.18k	0.17% $ 2.1m
Sarah Schlesinger	Independent Director	6.8yrs	US$367.25k	0.17% $ 2.0m
Mark DiPaolo	Independent Director	6.8yrs	US$396.59k	0.17% $ 2.0m

6.8yrs

Durée moyenne de l'emploi

52.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de INVA sont considérés comme expérimentés (ancienneté moyenne 6.8 ans).

Innoviva Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Chief Accounting Officer & Secretary recently sold US$154k worth of stock

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

Recent updates

Third quarter 2024 earnings released: EPS: US$0.019 (vs US$1.26 in 3Q 2023)

New minor risk - Earnings quality

Price target increased by 20% to US$18.00

New minor risk - Financial position

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.02 profit in 2Q 2023)

Benign Growth For Innoviva, Inc. (NASDAQ:INVA) Underpins Its Share Price

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer

New minor risk - Financial position

Innoviva: Potentially Overvalued

Now 21% undervalued

Why Innoviva's (NASDAQ:INVA) Shaky Earnings Are Just The Beginning Of Its Problems

First quarter 2024 earnings released: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Innoviva, Inc., Annual General Meeting, Jun 17, 2024

Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.’s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Full year 2023 earnings released: EPS: US$2.75 (vs US$3.07 in FY 2022)

Innoviva, Inc. Appoints David Altarac as Chief Medical Officer of Innoviva Specialty Therapeutics

Here's Why Innoviva (NASDAQ:INVA) Can Manage Its Debt Responsibly

Chief Accounting Officer & Secretary recently sold US$154k worth of stock

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Third quarter 2023 earnings released: EPS: US$1.26 (vs US$3.81 in 3Q 2022)

Innoviva, Inc. Appoints Stephen Basso as Chief Financial Officer

Innoviva Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Nasdaq’s Audit Committee Composition Requirements

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.02 (vs US$0.013 in 2Q 2022)

Innoviva, Inc. Announces Resignation of Deborah L. Birx as Member of the Board of Directors and Chair of the Audit Committee

Price target decreased by 23% to US$13.00

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 12% to US$15.17

Innoviva (NASDAQ:INVA) Seems To Use Debt Quite Sensibly

Full year 2022 earnings released: EPS: US$3.07 (vs US$3.24 in FY 2021)

Innoviva, Inc. Announces Appointment of Sapna Srivastava to the Board of Directors

Innoviva, Inc Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for $100 million worth of its shares.

Innoviva Stock? Not Yet. Short Puts? Definitely.

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 15% stake in Theravance Respiratory Company, LLC from Innoviva, Inc. (NasdaqGS:INVA).

Price target decreased to US$18.67

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX) from a group of shareholders.

Does Innoviva (NASDAQ:INVA) Have A Healthy Balance Sheet?

Continuing To Avoid Innoviva Inc.

First quarter 2022 earnings released: EPS: US$0.23 (vs US$0.93 in 1Q 2021)

Price target increased to US$20.50

We Think Innoviva (NASDAQ:INVA) Can Manage Its Debt With Ease

Taking Innoviva Winnings Off The Table, Again

Investor sentiment improved over the past week

Innoviva, Inc. (NasdaqGS:INVA) submitted a non-binding proposal to acquire all of the remaining shares of Entasis Therapeutics Holdings Inc. (NasdaqGM:ETTX).

Innoviva Inc.: Short Puts Are Compelling

Is Innoviva (NASDAQ:INVA) A Risky Investment?

Taking Profits In Innoviva Inc.

Independent Chairman of the Board recently bought US$264k worth of stock

Innoviva, Inc. (NasdaqGS:INVA) announces an Equity Buyback for 32,000,000 shares, representing 32% for $392 million.

First quarter 2021 earnings released: EPS US$0.93 (vs US$0.65 in 1Q 2020)

Innoviva reports Q1 results

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Innoviva, Inc. Appoints Deborah L. Birx to its Board of Directors

Is Weakness In Innoviva, Inc. (NASDAQ:INVA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Full year 2020 earnings released: EPS US$2.22 (vs US$1.56 in FY 2019)

Revenue beats expectations

Full year 2020 earnings released: EPS US$2.21 (vs US$1.56 in FY 2019)

Revenue beats expectations

Did Innoviva's (NASDAQ:INVA) Share Price Deserve to Gain 36%?

New 90-day high: US$12.51

These 4 Measures Indicate That Innoviva (NASDAQ:INVA) Is Using Debt Safely

Investor sentiment improved over the past week

New 90-day high: US$11.81

Innoviva, Inc. Enters into Strategic Partnership with Sarissa Capital Management LP